Collagen Medical

Executive Summary

Collagen Medical LLC is a Boston-based pre-clinical stage specialty pharmaceutical company developing targeted MRI contrast agents for the diagnosis, staging, and monitoring of fibrotic diseases, including those affecting the heart, liver, and lungs. The company's technology aims to provide highly sensitive, 3D mapping of fibrosis to guide therapy and assess treatment response. Despite being founded in 2008, Collagen Medical remains in the pre-clinical phase, focusing on advancing its lead candidate through necessary studies to support an Investigational New Drug (IND) application. The fibrosis imaging market represents a significant opportunity given the high prevalence of fibrotic diseases and the limitations of current diagnostic methods. The company's success hinges on demonstrating preclinical proof-of-concept, safety, and efficacy. With no disclosed funding rounds or revenue, Collagen Medical likely relies on grants, angel investors, or strategic partnerships. The path to clinical trials is capital-intensive, and the company will need to secure additional financing or partnerships to progress. Given the early stage and lack of public data, the risk is high, but the potential for a novel diagnostic tool in a large underserved market remains compelling.

Upcoming Catalysts (preview)

• Q4 2026Completion of preclinical efficacy studies in animal models55% success
• Q2 2027IND filing with the FDA30% success
• Q3 2026Strategic partnership or licensing deal for fibrosis indication25% success